Regulating personalised medicines 14-15th April 2003, Surrey, UK The unravelling of the human genome and advances in genetic research are now opening up new horizons in the understanding of [...]
Risk management workshop: Identifying and developing effective stakeholder communication during drug development 12-13th December 2002, Washington DC, USA "Risk is complex and in managing it we must be aware [...]
In 2001, CMR International conducted a study among pharmaceutical companies to evaluate their experience with regulatory authorities in Asia Pacific regarding the acceptance of foreign clinical data and adoption [...]
The ICH E5 Guideline was introduced in February 1998 and subsequently implemented by the regulatory authorities of the USA, EU and Japan. The purpose of this guideline is to [...]
Risk management: The role of regulatory strategies in the development of new medicines 25-26th April 2002, Surrey, UK The primary objective of the meeting was to develop a global [...]
CMR International R&D Briefing 31 - Profile of performance: Review times - is there still room for improvement? Key messages: Performance improvement initiatives established by regulatory authorities in the [...]